TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Google Secures Pentagon AI Deal for Classified Projects 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
JERSEY CITY, N.J., Feb. 03, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences in February:
- Leerink Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria Hotel in New York City on Thursday, February 11, 2016 at 8:55 a.m. ET; and
- RBC Capital Markets 2016 Healthcare Conference at the New York Palace Hotel in New York City on Wednesday, February 24, 2016 at 11:30 a.m. ET.
A live webcast of each presentation will be available on the investors section of the Company's website: www.scynexis.com. A replay of each presentation will be available approximately two hours after each event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS, Inc. is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
